Search by CAS No , Chemical Name or Molecular Formula
"Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
Denosumab is contraindicated in people with low blood calcium levels.
The most common side effects are joint and muscle pain in the arms or legs.
Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone. It was developed by the biotechnology company Amgen.",""
Pageau, Steven C. (2009); "Prolia (denosumab)". Products. Amgen. Retrieved 6 May 2012.
We normally respond within 8 hours.
This page contains information about Denosumab Cas # 615258-40-7 and its Peptides.
Denosumab Denosumab Worldwide Suppliers of Denosumab https://www.clearsynth.com/en/CSO11193.html Peptides Clearsynth 615258-40-7
Product rating: 9 Denosumab based on 20 ratings
Keywords: Peptides CS-O-11193 Denosumab Denosumab 615258-40-7 6446.27 C283H461N85O85S
Specific product requirements
CLEARSYNTH CANADA INC.
2395 Speakman Drive,
Lab: 1001, Mississauga, ON,
Canada L5K 1B3
T : +1-289-729-0060
CLEARSYNTH RESEARCH CENTRE
Plot No. 177, IDA, Mallapur,
T : +91-40-27155481
CLEARSYNTH LABS LTD
17, Lotus Business Park,
Andheri (W), Mumbai - 400053
T : +91-22-45045945